Opened in 1969 this former Sterling Drug facility provides Contract Development and Manufacturing services.
The 450 M3 reactor manufacturing capacity available on the site allows for rapid entry for new products to full cGMP (Current Good Manufacturing Practice).
The Dudley site produces clinical trial and commercial quantities of API (Active Pharmaceutical Ingredients) product from grams to tonnes per annum.
The site is spread over an area of 169,900 sq. metres.
The R&D facility on site has 50 scientists, focussed on process development and industrialisation support with extensive hazard evaluation capability.
cGMP (Current Good Manufacturing Practice) Pilot Plant.
Dudley has three main plant areas which can perform demanding and hazardous chemistry such as hydrogenation, halogenation, Friedel-Crafts and cyanation.
The site is approved by MHRA (Medical Health Regulatory Authority), PMDA and FDA approved with the last FDA inspection in 2011.